Sofdra
(Sofpironium Bromide, 15%)Phase 3Small molecule
Sofdra is one of 15 small molecule programs targeting Hyperhidrosis. It is currently in Phase 3.
1
Indications
4
Total Trials
0
Active Trials
14
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
20
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
31 competitors in Hyperhidrosis
#DrugCompanyPhaseTrials
1Oxytrol
WWim Janssens
Approved
Botulinum Toxin a
GSKApproved
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
GSK1358820
GSKPhase 3
Botox
RRevance Therapeutics, Inc.
Phase 2
Meditoxin
MMedy-Tox
Phase 3
Botox
AbbViePhase 2
Sofdra
BBotanix Pharmaceuticals
Phase 3
Glycopyrronium Bromide
NovartisPhase 2
Incruse Ellipta
GGlaxo Dba Glaxosmithkline
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hyperhidrosis4 trials
Regulatory
FDA Approval Timeline[4]
Jun 18, 2024
SOFDRA
NDA NDA217347
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sofpironium Bromide, 15%. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Sofdra. U.S. Food & Drug Administration.
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBotanix Pharmaceuticals